These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.
Merck & Co. struck a deal with Brazil's Butantan Institute to push ahead with their respective dengue development programs.
As biopharma companies take steps to become more digitally savvy, who should lead the charge? It’s time to identify a digital leadership model.
BMS’s Opdivo failed a key small cell lung cancer trial in October, but the results may still be enough to protect the approval it already has.
India’s stock regulators say they're examining a whistleblower complaint against top domestic drugmaker Sun Pharma.
Leerink analysts predict a doubling of competitive intensity in 15 disease areas by 2023, putting a dozen companies at risk.
Last May, Neurocrine’s Ingrezza failed a Tourette syndrome trial, prompting the company to design a new one. But the drug has failed that trial, too.
After Merck abandoned its Lantus biosimilar, Mylan is still pressing forward and won a patent challenge against Sanofi.
With about $225 million in hand from the IPO, Orchard Therapeutics is starting on a plant in California for its gene therapy candidates.
Alnylam and Ionis have until just after the start of the new year to appeal NICE's conclusion that their new ATTR drugs are not cost-effective.
Johnson & Johnson’s Tremfya may have debuted behind Novartis' Cosentyx, but it has now topped the blockbuster in a head-to-head trial.